Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma

被引：0

作者：

Weller, Michael

Papachristodoulou, Alexandros

Hentschel, Bettina

Gramatzki, Dorothee

Felsberg, Joerg

Loeffler, Markus

Schackert, Gabriele

Westphal, Manfred

Tonn, Joerg

Silginer, Manuela

von Deimling, Andreas

Pietsch, Torsten

Reifenberger, Guido

Roth, Patrick

机构：

[1] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[2] Univ Leipzig, Inst Med Informat Stat & Epidemol, Leipzig, Germany

[3] Heinrich Heine Univ Hosp, Dept Neuropathol, Dusseldorf, Germany

[4] Univ Hosp Dresden, Dept Neurosurg, Dresden, Germany

[5] Univ Hamburg, Dept Neurosurg, Hamburg, Germany

[6] Univ Munich LMU, Dept Neurosurg, Munich, Germany

[7] Heidelberg Univ, Dept Neuropathol, Heidelberg, Germany

[8] Univ Bonn, Dept Neuropathol, Bonn, Germany

[9] Univ Hosp Zurich, Zurich, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.2013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2013

引用

页数：1

共 50 条

[31] TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?
Giannini, Caterina
Giangaspero, Felice
NEURO-ONCOLOGY, 2021, 23 (06) : 865 - 866
[32] Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Tremont-Lukats, Ivo W.
Teh, Bin S.
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S589 - S591
[33] Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma
Seidel, Clemens
Kortmann, Rolf-Dieter
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (09) : 855 - 856
[34] The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis
Huy Gia Vuong
Thu Quynh Nguyen
Tam N. M. Ngo
Hoang Cong Nguyen
Kar-Ming Fung
Ian F. Dunn
BMC Cancer, 20
[35] Predicting TERT promoter mutation using MR images in patients with witd-type IDH1 glioblastoma
Yamashita, K.
Hatae, R.
Hiwatashi, A.
Togao, O.
Kikuchi, K.
Momosaka, D.
Yamashita, Y.
Kuga, D.
Hata, N.
Yoshimoto, K.
Suzuki, S. O.
Iwaki, T.
Iihara, K.
Honda, H.
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2019, 100 (7-8) : 411 - 419
[36] A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
Arita, Hideyuki
Yamasaki, Kai
Matsushita, Yuko
Nakamura, Taishi
Shimokawa, Asanao
Takami, Hirokazu
Tanaka, Shota
Mukasa, Akitake
Shirahata, Mitsuaki
Shimizu, Saki
Suzuki, Kaori
Saito, Kuniaki
Kobayashi, Keiichi
Higuchi, Fumi
Uzuka, Takeo
Otani, Ryohei
Tamura, Kaoru
Sumita, Kazutaka
Ohno, Makoto
Miyakita, Yasuji
Kagawa, Naoki
Hashimoto, Naoya
Hatae, Ryusuke
Yoshimoto, Koji
Shinojima, Naoki
Nakamura, Hideo
Kanemura, Yonehiro
Okita, Yoshiko
Kinoshita, Manabu
Ishibashi, Kenichi
Shofuda, Tomoko
Kodama, Yoshinori
Mori, Kanji
Tomogane, Yusuke
Fukai, Junya
Fujita, Koji
Terakawa, Yuzo
Tsuyuguchi, Naohiro
Moriuchi, Shusuke
Nonaka, Masahiro
Suzuki, Hiroyoshi
Shibuya, Makoto
Maehara, Taketoshi
Saito, Nobuhito
Nagane, Motoo
Kawahara, Nobutaka
Ueki, Keisuke
Yoshimine, Toshiki
Miyaoka, Etsuo
Nishikawa, Ryo
ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2016, 4 : 79
[37] A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
Hideyuki Arita
Kai Yamasaki
Yuko Matsushita
Taishi Nakamura
Asanao Shimokawa
Hirokazu Takami
Shota Tanaka
Akitake Mukasa
Mitsuaki Shirahata
Saki Shimizu
Kaori Suzuki
Kuniaki Saito
Keiichi Kobayashi
Fumi Higuchi
Takeo Uzuka
Ryohei Otani
Kaoru Tamura
Kazutaka Sumita
Makoto Ohno
Yasuji Miyakita
Naoki Kagawa
Naoya Hashimoto
Ryusuke Hatae
Koji Yoshimoto
Naoki Shinojima
Hideo Nakamura
Yonehiro Kanemura
Yoshiko Okita
Manabu Kinoshita
Kenichi Ishibashi
Tomoko Shofuda
Yoshinori Kodama
Kanji Mori
Yusuke Tomogane
Junya Fukai
Koji Fujita
Yuzo Terakawa
Naohiro Tsuyuguchi
Shusuke Moriuchi
Masahiro Nonaka
Hiroyoshi Suzuki
Makoto Shibuya
Taketoshi Maehara
Nobuhito Saito
Motoo Nagane
Nobutaka Kawahara
Keisuke Ueki
Toshiki Yoshimine
Etsuo Miyaoka
Ryo Nishikawa
Acta Neuropathologica Communications, 4
[38] FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF CCNU AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA
Lazaridis, Lazaros
Bumes, Elisabeth
Spille, Dorothee Cacilia
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Feldheim, Jonas
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Breuer, Stella
Hattingen, Elke
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
NEURO-ONCOLOGY, 2022, 24 : 74 - 74
[39] FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA
Lazaridis, L.
Schmidt, T.
Agkatsev, S.
Blau, T.
Spille, D.
Heider, S.
Schulz, T.
Bumes, E.
Oster, C.
Feldheim, J.
Stummer, W.
Kessler, A.
Seidel, C.
Hau, P.
Sure, U.
Keyvani, K.
Herrlinger, U.
Kleinschnitz, C.
Stuschke, M.
Herrmann, K.
Deuschl, C.
Hattingen, E.
Scheffler, B.
Kebir, S.
Glas, M.
NEURO-ONCOLOGY, 2022, 24
[40] First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
Lazaridis, Lazaros
Bumes, Elisabeth
Spille, Dorothee Caecilia
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Feldheim, Jonas
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Breuer, Stella
Hattingen, Elke
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)

← 1 2 3 4 5 →